The magnitude of the miss and guidance cut signals worsening payer dynamics and execution challenges in Prenatal Health. Watch for further details on the Ascend restructuring and any strategic portfolio review outcomes. The stock is likely to trade down sharply; consider short-term bearish positioning until visibility improves.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $2.86entry
- T+1 · 4mo ago +5.59%α +4.17% · $3.02
- T+5 · 3mo ago +13.99%α +10.47% · $3.26
- T+20 · 3mo ago +10.49%α +7.50% · $3.16
- T+60 · 22d ago +110.49%α +108.03% · $6.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline, 7.4% below consensus) and adjusted EPS of -$0.25 (vs consensus -$0.06, a 317% miss). The company lowered full-year 2026 revenue guidance to $770-790M and suspended Adjusted EBITDA guidance, citing payer friction, Prenatal Health volume declines, and a $11M revenue reduction from prior-period collection estimate changes.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $190.7M vs consensus $206.0M (-7.4% miss) and vs $213.1M YoY (-11%)
- Adjusted EPS -$0.25 vs consensus -$0.06 (-316.7% miss); GAAP EPS -$0.46
- Full-year 2026 revenue guidance lowered to $770-790M (from undisclosed prior range); Adjusted EBITDA guidance suspended
- Prenatal Health revenue fell 16% YoY on 9% volume decline; Cancer Care Continuum revenue down 11% YoY despite 6% volume growth
- Gross margin 66.6% vs 71.2% YoY, down 460 bps
- Operating cash outflow $8.3M; adjusted free cash flow -$10.9M; cash $115.2M
- Company launched Ascend initiative with professional services firm to improve efficiency and scalability
Financial Impact
Revenue miss of $15.3M vs consensus; EPS miss of $0.19; guidance cut implies ~$20-30M reduction at midpoint vs prior expectations
Risk Factors
- Continued payer friction and reimbursement pressure on hereditary cancer testing
- Prenatal Health volume declines may persist
- Cash burn ($34.5M in H1 2026) could necessitate financing if trends continue
- Execution risk on Ascend initiative and strategic review
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3336418 |
Track record
16 reports on MYGN
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry price pending
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
- Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
- Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers